Cytocom, Inc.
CBLI · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $2 |
| % Growth | -76.4% | -2.2% | -41.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $1 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $1 | $2 | $4 | $5 |
| G&A Expenses | $2 | $2 | $2 | $3 |
| SG&A Expenses | $2 | $2 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $6 | $8 |
| Operating Income | -$3 | -$2 | -$5 | -$6 |
| % Margin | -983.7% | -212% | -421.7% | -287.5% |
| Other Income/Exp. Net | $0 | -$1 | $1 | -$4 |
| Pre-Tax Income | -$2 | -$3 | -$4 | -$10 |
| Tax Expense | $0 | -$0 | $1 | -$4 |
| Net Income | -$2 | -$3 | -$4 | -$10 |
| % Margin | -912.2% | -237.7% | -317.3% | -498.2% |
| EPS | -0.19 | -0.23 | -0.32 | -0.87 |
| % Growth | 17.4% | 28.1% | 63.2% | – |
| EPS Diluted | -0.19 | -0.23 | -0.32 | -0.87 |
| Weighted Avg Shares Out | 12 | 11 | 11 | 11 |
| Weighted Avg Shares Out Dil | 12 | 11 | 11 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$4 | -$10 |
| % Margin | -907.8% | -236.5% | -315.7% | -497.1% |